سيدني، أستراليا, Aug. 08, 2024 (GLOBE NEWSWIRE) — في الصيف الماضي، أطلقت شركة “اكسي” الرائدة عالميًا في مجال تداول العملات الأجنبية والعقود مقابل الفروقات، برنامج “اكسي سيليكت”، وهو برنامج رائد لتخصيص رأس المال يوفر للمتداولين الطموحين الفرصة للتقدم نحو التداول الاحترافي. على مدار العام الماضي، انضم آلاف المتداولين إلى برنامج “اكسي سيليكت”، وهم الآن يشاركون قصص نجاحهم من خلال سلسلة جديدة بعنوان “Axi Select Talks“.
“أولاً، ليس عليك دفع رسوم اشتراك، فقط إيداع حد أدنى.
وهم يمنحونك حقًا فرصة لكسب المال… لديهم بعض القواعد الواضحة التي تناسب الطرفين، وليس فقط الوسيط”، هذا ما يقوله “جيرالد وينترسبيرجر”، مهندس البرمجيات، عند الحديث عن برنامج “اكسي سيليكت”. بصفته متداولًا متمرسًا، فهو أول من وصل إلى مرحلة “برو” (Pro) في البرنامج والان يحرز تقدمًا ثابتًا نحو تأمين تمويل بقيمة 1,000,000 دولار. سيتم عرض قصص متداولين آخرين مثل “جيرالد” في سلسلة بودكاست “Axi Select Talks“.
في أعقاب الاحداث الأخيرة التي هزت صناعة التداول الممول وأدت إلى إغلاق العديد من الشركات، يبدو أن برنامج “اكسي سيليكت” هو الخيار الأكثر صدقا. تم تصميم نموذج البرنامج الذي يركز على تجربة المتداول بهدف توفير مسار عادل لهم للوصول إلى تمويل رأسمالي يصل إلى 1,000,000 دولار أمريكي وفرصة لكسب ما يصل إلى 90٪ من أرباحهم. علاوة على ذلك، يستطيع المتداولون الانضمام إلى البرنامج دون رسوم تسجيل، بالإضافة إلى الاستفادة من ظروف تداول غير مقيدة وغرفة تداول حصرية.
برنامج “اكسي سيليكت” متاح فقط لعملاء شركة AxiTrader Limited. تحمل العقود مقابل الفروقات (CFDs) مخاطر عالية لخسارة الاستثمار. في تعاملاتنا معك، سنكون الطرف المقابل الرئيسي لجميع مراكزك. هذا المحتوى غير متاح للمقيمين في أستراليا، نيوزيلندا، الاتحاد الأوروبي والمملكة المتحدة. لمزيد من المعلومات، يُرجى الرجوع إلى شروط الخدمة الخاصة بنا. تطبق رسوم التداول الاعتيادية.
عن شركة “اكسي”
شركة “اكسي” هي شركة وساطة عالمية لتداول العملات الأجنبية والعقود مقابل الفروقات عبر الإنترنت، وتضم الآلاف من العملاء في أكثر من 100 دولة حول العالم.
تقدم شركة “اكسي” العقود مقابل الفروقات للعديد من فئات الأصول بما في ذلك تداول العملات الأجنبية والأسهم والذهب والنفط والقهوة والمزيد من الأصول الأخرى.
في شركة “اكسي”، نحن نفخر بسمعتنا كوسيط صادق وعادل، حيث نقدم لعملائنا خدمة وظروف تداول متميزة منذ عام 2007. بالإضافة إلى ذلك، فإننا نعمل مع السلطات التنظيمية الحاكمة في جميع أنحاء العالم لضمان تجاوزنا لأعلى معايير الصناعة.
Operational complementarities expected to yield annual synergies of approximately $100 million
Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform
Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods
Highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months
Industry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion overall before potential royalties over the course of the partnership
Well-capitalized balance sheet with approximately $850 million in cash and cash equivalents between the two companies as of the end of Q2 2024
Operational complementarities expected to yield annual synergies in excess of $100 million
SALT LAKE CITY and OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) today announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster.
“We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion as well as the planned CEO of the combined entity. “Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started.”
“Adding Exscientia’s best-in-class focused precision oncology internal pipeline to Recursion’s first-in-class focused pipeline spanning rare disease, precision oncology and infectious disease is highly complementary as we look to bring treatments to patients faster,” said David Hallett, Ph.D., Interim Chief Executive Officer and planned Chief Scientific Officer of Recursion post-closing of the transaction. “We look forward to bringing our teams together and integrating Recursion’s high throughput and target biology capabilities with Exscientia’s highly scalable molecular design and automated chemistry synthesis capabilities to truly accelerate the discovery of better drugs for patients.”
Once integrated, the companies believe the extended and evolved Recursion OS will enable the discovery and translation of higher quality medicines more efficiently and at a higher scale with a full-stack technology-enabled small molecule discovery platform. In addition, the combined company expects to read out approximately 10 clinical trials in the next 18 months.
The proposed business combination will also advance significant therapeutic discovery collaborations with some of the most prominent biopharma companies in the world, including Roche-Genentech, Sanofi, Bayer, and Merck KGaA. Moreover, there is the potential for approximately $200 million in milestone payments over the next 2 years from these current partnerships and there is the potential for more than $20 billion in revenue before royalties on net-sales of partnership programs which range from mid single-digit to double-digit royalties over the course of the partnership.
Recursion & Exscientia Combined Pipeline
Recursion & Exscientia Combined Pipeline
Strategic Rationale
Pipeline: The combination would create a diverse portfolio of clinical and near-clinical programs (approximately 10 clinical readouts expected in the next 18 months) where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion. In addition to Recursion’s internal pipeline, Exscientia has wholly-owned oncology programs associated with targets CDK7 (clinical), LSD1, and MALT1 as well as partnered programs associated with targets PKC-Theta (clinical) and ENPP1. Across the combined pipeline there is no competitive overlap, with Recursion’s pipeline focusing on first-in-class drug candidates within oncology, rare disease, and infectious disease and Exscientia’s focus on best-in-class drug candidates within oncology. Additionally, for both companies there are many research and discovery stage pipeline programs that would benefit from the complementary combination of the two platforms.
Partnerships: The proposed business combination would bring together transformational partnerships with leading large pharma companies with a total of 10 programs already optioned across oncology and immunology. In addition to Recursion’s transformational partnerships with Roche-Genentech (neuroscience and a gastrointestinal oncology indication) and Bayer (undruggable oncology), Exscientia has partnerships with Sanofi (immunology and oncology) and Merck KGaA (oncology and immunology). In addition, Exscientia has a partnership with BMS (oncology and immunology) where an optioned program related to PKC-Theta has already shown positive early Phase 1 results. Furthermore, the combined company expects potential additional milestone payments of approximately $200 million over the next 2 years from its current partnerships.
Platform: The combination will help enable a full-stack technology-enabled platform spanning patient-centric target discovery, structure based drug design including hotspot analysis, quantum mechanics and molecular dynamics modeling, 2D and 3D generative AI design, encode and automate design-make-test-learn cycles with active learning, automated chemical synthesis, predictive ADMET and translation, biomarker selection, clinical development, and more. Furthermore, Exscientia’s automated chemistry design and synthesis capabilities are expected to allow Recursion to more rapidly and effectively run SAR cycles during hit to lead and lead optimization. These capabilities are expected to generate diverse chemistry to experimentally improve our predictive maps of biology and chemistry.
Transaction Details
Under the terms of the transaction agreement, which were unanimously approved by the boards of directors of both companies, Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share they own, with fractional shares paid in cash. Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% and Exscientia shareholders will own approximately 26% of the combined company, in each case assuming no additional issuance by either company before closing. Major shareholders of each company, including holders of more than 40% of Exscientia shares, have entered into agreements on customary terms and conditions under which they have agreed to vote all their shares in favor of the transaction. There is approximately $850 million in cash and cash equivalents held by both companies at the end of Q2 2024. The combined company is estimated to achieve annual synergies of approximately $100 million with a runway extending into 2027.
The combination is expected to be implemented through a court sanctioned scheme of arrangement under English law and is subject to the satisfaction of customary closing conditions, including the approval of Exscientia shareholders, the approval of Recursion’s stockholders, and the sanction of the High Court of Justice of England and Wales, and the receipt of required regulatory approvals. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by early 2025.
Listing, Governance and Management
The combined company, which will be named Recursion, will continue to be headquartered in Salt Lake City, Utah, and trade on the NASDAQ, while maintaining a significant presence in the U.K. Chris Gibson, Ph.D., Co-Founder & CEO of Recursion, will serve as CEO of the combined company and David Hallett, Ph.D., Interim Chief Executive Officer & Chief Scientific Officer of Exscientia, plans to join the combined company as Chief Scientific Officer. Two existing Exscientia directors will join the Board of Recursion following the closing of the transaction.
Advisors
Allen & Company LLC acted as exclusive financial advisor to Recursion and Wilson Sonsini Goodrich & Rosati acted as legal counsel. Centerview Partners LLC acted as exclusive financial advisor to Exscientia and A&O Shearman acted as legal counsel.
About Recursion
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area and London.
About Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.
Forward Looking Statements
Statements contained herein which are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the proposed business combination of Recursion and Exscientia and the outlook for Recursion’s or Exscientia’s future business and financial performance such as delivering better treatments to patients, faster and at a lower cost; the discovery and translation of higher quality medicines more efficiently and at a higher scale; helping to enable a full-stack technology-enabled platform; allowing Recursion to more rapidly and effectively run SAR cycles during hit to lead optimization; generating the diverse chemistry to experimentally improve predictive maps; the number and timing of clinical program readouts over the next 18 months; the combined company’s first-in-class and best-in-class opportunities; potential for sales from successful programs with annual peak sales opportunities of over $1 billion each; potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion in revenue before royalties over the course of the partnerships; percentage of the combined company to be received by Exscientia shareholders; cash runway extending into 2027; the value of estimated annual synergies; implementing the combination through a UK scheme of arrangement; the expected closing of the transaction by early 2025; continuing to build the best example of the next generation of biotechnology companies; the plans for David Hallett, Ph.D. to join the combined company as Chief Scientific Officer; and many others. Such forward-looking statements are based on the current beliefs of Recursion’s and Exscientia’s respective management as well as assumptions made by and information currently available to them, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may vary materially from these forward-looking statements based on a variety of risks and uncertainties including: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the inability to obtain Recursion’s stockholder approval or Exscientia’s shareholder approval or the failure to satisfy other conditions to completion of the proposed combination, including obtaining the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement, on a timely basis or at all, and the receipt of required regulatory approvals; risks that the proposed combination disrupts each company’s current plans and operations; the diversion of the attention of the respective management teams of Recursion and Exscientia from their respective ongoing business operations; the ability of either Recursion, Exscientia or the combined company to retain key personnel; the ability to realize the benefits of the proposed combination, including cost synergies; the ability to successfully integrate Exscientia’s business with Recursion’s business, at all or in a timely manner; the outcome of any legal proceedings that may be instituted against Recursion, Exscientia or others following announcement of the proposed combination; the amount of the costs, fees, expenses and charges related to the proposed combination; the effect of economic, market or business conditions, including competition, regulatory approvals and commercializing drug candidates, or changes in such conditions, have on Recursion’s, Exscientia’s and the combined company’s operations, revenue, cash flow, operating expenses, employee hiring and retention, relationships with business partners, the development or launch of technology enabled drug discovery, and commercializing drug candidates; the risks of conducting Recursion’s and Exscientia’s business internationally; the impact of changes in interest rates by the Federal Reserve and other central banks; the impact of potential inflation, volatility in foreign currency exchange rates and supply chain disruptions; the ability to maintain technology-enabled drug discovery in the biopharma industry; and risks relating to the market value of Recursion’s common stock to be issued in the proposed combination.
Other important factors and information are contained in Recursion’s most recent Annual Report on Form 10-K and Exscientia’s most recent Annual Report on Form 20-F, including the risks summarized in the section entitled “Risk Factors,” Recursion’s most recent Quarterly Reports on Form 10-Q and Exscientia’s filing on Form 6-K filed May 21, 2024, and each company’s other periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed at https://ir.recursion.com in the case of Recursion, http://investors.exscientia.ai in the case of Exscientia, or www.sec.gov. All forward-looking statements are qualified by these cautionary statements and apply only as of the date they are made. Neither Recursion nor Exscientia undertakes any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional Information and Where to Find It
This communication relates to a proposed business combination of Recursion and Exscientia that will become the subject of a joint proxy statement to be filed by Recursion with the SEC. The joint proxy statement will provide full details of the proposed combination and the attendant benefits and risks, including the terms and conditions of the scheme of arrangement and the other information required to be provided to Exscientia’s shareholders under the applicable provisions of the U.K. Companies Act 2006. This communication is not a substitute for the joint proxy statement or any other document that Recursion or Exscientia may file with the SEC or send to their respective stockholders in connection with the proposed combination. Investors and security holders are urged to read the definitive joint proxy statement and all other relevant documents filed with the SEC or sent to Recursion’s stockholders or Exscientia’s shareholders as they become available because they will contain important information about the proposed combination. All documents, when filed, will be available free of charge at the SEC’s website (www.sec.gov). You may also obtain these documents by contacting Recursion’s Investor Relations department at investor@recursion.com; or by contacting Exscientia’s Investor Relations department at investors@exscientia.ai. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.
Participants in the Solicitation
Recursion, Exscientia and their respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed business combination. Information about Recursion’s directors and executive officers is available in Recursion’s proxy statement dated April 23, 2024 for its 2024 Annual Meeting of Stockholders. Information about Exscientia’s directors and executive officers is available in Exscientia’s proxy statement dated March 21, 2024 for its 2024 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement and all other relevant materials to be filed with the SEC regarding the proposed combination when they become available. Investors should read the joint proxy statement carefully when it becomes available before making any voting or investment decisions.
Operational complementarities expected to yield annual synergies of approximately $100 million
Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform
Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods
Highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months
Industry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion overall before potential royalties over the course of the partnership
Well-capitalized balance sheet with approximately $850 million in cash and cash equivalents between the two companies as of the end of Q2 2024
Operational complementarities expected to yield annual synergies in excess of $100 million
SALT LAKE CITY and OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) today announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster.
“We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion as well as the planned CEO of the combined entity. “Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started.”
“Adding Exscientia’s best-in-class focused precision oncology internal pipeline to Recursion’s first-in-class focused pipeline spanning rare disease, precision oncology and infectious disease is highly complementary as we look to bring treatments to patients faster,” said David Hallett, Ph.D., Interim Chief Executive Officer and planned Chief Scientific Officer of Recursion post-closing of the transaction. “We look forward to bringing our teams together and integrating Recursion’s high throughput and target biology capabilities with Exscientia’s highly scalable molecular design and automated chemistry synthesis capabilities to truly accelerate the discovery of better drugs for patients.”
Once integrated, the companies believe the extended and evolved Recursion OS will enable the discovery and translation of higher quality medicines more efficiently and at a higher scale with a full-stack technology-enabled small molecule discovery platform. In addition, the combined company expects to read out approximately 10 clinical trials in the next 18 months.
The proposed business combination will also advance significant therapeutic discovery collaborations with some of the most prominent biopharma companies in the world, including Roche-Genentech, Sanofi, Bayer, and Merck KGaA. Moreover, there is the potential for approximately $200 million in milestone payments over the next 2 years from these current partnerships and there is the potential for more than $20 billion in revenue before royalties on net-sales of partnership programs which range from mid single-digit to double-digit royalties over the course of the partnership.
Recursion & Exscientia Combined Pipeline
Recursion & Exscientia Combined Pipeline
Strategic Rationale
Pipeline: The combination would create a diverse portfolio of clinical and near-clinical programs (approximately 10 clinical readouts expected in the next 18 months) where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion. In addition to Recursion’s internal pipeline, Exscientia has wholly-owned oncology programs associated with targets CDK7 (clinical), LSD1, and MALT1 as well as partnered programs associated with targets PKC-Theta (clinical) and ENPP1. Across the combined pipeline there is no competitive overlap, with Recursion’s pipeline focusing on first-in-class drug candidates within oncology, rare disease, and infectious disease and Exscientia’s focus on best-in-class drug candidates within oncology. Additionally, for both companies there are many research and discovery stage pipeline programs that would benefit from the complementary combination of the two platforms.
Partnerships: The proposed business combination would bring together transformational partnerships with leading large pharma companies with a total of 10 programs already optioned across oncology and immunology. In addition to Recursion’s transformational partnerships with Roche-Genentech (neuroscience and a gastrointestinal oncology indication) and Bayer (undruggable oncology), Exscientia has partnerships with Sanofi (immunology and oncology) and Merck KGaA (oncology and immunology). In addition, Exscientia has a partnership with BMS (oncology and immunology) where an optioned program related to PKC-Theta has already shown positive early Phase 1 results. Furthermore, the combined company expects potential additional milestone payments of approximately $200 million over the next 2 years from its current partnerships.
Platform: The combination will help enable a full-stack technology-enabled platform spanning patient-centric target discovery, structure based drug design including hotspot analysis, quantum mechanics and molecular dynamics modeling, 2D and 3D generative AI design, encode and automate design-make-test-learn cycles with active learning, automated chemical synthesis, predictive ADMET and translation, biomarker selection, clinical development, and more. Furthermore, Exscientia’s automated chemistry design and synthesis capabilities are expected to allow Recursion to more rapidly and effectively run SAR cycles during hit to lead and lead optimization. These capabilities are expected to generate diverse chemistry to experimentally improve our predictive maps of biology and chemistry.
Transaction Details
Under the terms of the transaction agreement, which were unanimously approved by the boards of directors of both companies, Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share they own, with fractional shares paid in cash. Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% and Exscientia shareholders will own approximately 26% of the combined company, in each case assuming no additional issuance by either company before closing. Major shareholders of each company, including holders of more than 40% of Exscientia shares, have entered into agreements on customary terms and conditions under which they have agreed to vote all their shares in favor of the transaction. There is approximately $850 million in cash and cash equivalents held by both companies at the end of Q2 2024. The combined company is estimated to achieve annual synergies of approximately $100 million with a runway extending into 2027.
The combination is expected to be implemented through a court sanctioned scheme of arrangement under English law and is subject to the satisfaction of customary closing conditions, including the approval of Exscientia shareholders, the approval of Recursion’s stockholders, and the sanction of the High Court of Justice of England and Wales, and the receipt of required regulatory approvals. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by early 2025.
Listing, Governance and Management
The combined company, which will be named Recursion, will continue to be headquartered in Salt Lake City, Utah, and trade on the NASDAQ, while maintaining a significant presence in the U.K. Chris Gibson, Ph.D., Co-Founder & CEO of Recursion, will serve as CEO of the combined company and David Hallett, Ph.D., Interim Chief Executive Officer & Chief Scientific Officer of Exscientia, plans to join the combined company as Chief Scientific Officer. Two existing Exscientia directors will join the Board of Recursion following the closing of the transaction.
Advisors
Allen & Company LLC acted as exclusive financial advisor to Recursion and Wilson Sonsini Goodrich & Rosati acted as legal counsel. Centerview Partners LLC acted as exclusive financial advisor to Exscientia and A&O Shearman acted as legal counsel.
About Recursion
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area and London.
About Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.
Forward Looking Statements
Statements contained herein which are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the proposed business combination of Recursion and Exscientia and the outlook for Recursion’s or Exscientia’s future business and financial performance such as delivering better treatments to patients, faster and at a lower cost; the discovery and translation of higher quality medicines more efficiently and at a higher scale; helping to enable a full-stack technology-enabled platform; allowing Recursion to more rapidly and effectively run SAR cycles during hit to lead optimization; generating the diverse chemistry to experimentally improve predictive maps; the number and timing of clinical program readouts over the next 18 months; the combined company’s first-in-class and best-in-class opportunities; potential for sales from successful programs with annual peak sales opportunities of over $1 billion each; potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion in revenue before royalties over the course of the partnerships; percentage of the combined company to be received by Exscientia shareholders; cash runway extending into 2027; the value of estimated annual synergies; implementing the combination through a UK scheme of arrangement; the expected closing of the transaction by early 2025; continuing to build the best example of the next generation of biotechnology companies; the plans for David Hallett, Ph.D. to join the combined company as Chief Scientific Officer; and many others. Such forward-looking statements are based on the current beliefs of Recursion’s and Exscientia’s respective management as well as assumptions made by and information currently available to them, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may vary materially from these forward-looking statements based on a variety of risks and uncertainties including: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the inability to obtain Recursion’s stockholder approval or Exscientia’s shareholder approval or the failure to satisfy other conditions to completion of the proposed combination, including obtaining the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement, on a timely basis or at all, and the receipt of required regulatory approvals; risks that the proposed combination disrupts each company’s current plans and operations; the diversion of the attention of the respective management teams of Recursion and Exscientia from their respective ongoing business operations; the ability of either Recursion, Exscientia or the combined company to retain key personnel; the ability to realize the benefits of the proposed combination, including cost synergies; the ability to successfully integrate Exscientia’s business with Recursion’s business, at all or in a timely manner; the outcome of any legal proceedings that may be instituted against Recursion, Exscientia or others following announcement of the proposed combination; the amount of the costs, fees, expenses and charges related to the proposed combination; the effect of economic, market or business conditions, including competition, regulatory approvals and commercializing drug candidates, or changes in such conditions, have on Recursion’s, Exscientia’s and the combined company’s operations, revenue, cash flow, operating expenses, employee hiring and retention, relationships with business partners, the development or launch of technology enabled drug discovery, and commercializing drug candidates; the risks of conducting Recursion’s and Exscientia’s business internationally; the impact of changes in interest rates by the Federal Reserve and other central banks; the impact of potential inflation, volatility in foreign currency exchange rates and supply chain disruptions; the ability to maintain technology-enabled drug discovery in the biopharma industry; and risks relating to the market value of Recursion’s common stock to be issued in the proposed combination.
Other important factors and information are contained in Recursion’s most recent Annual Report on Form 10-K and Exscientia’s most recent Annual Report on Form 20-F, including the risks summarized in the section entitled “Risk Factors,” Recursion’s most recent Quarterly Reports on Form 10-Q and Exscientia’s filing on Form 6-K filed May 21, 2024, and each company’s other periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed at https://ir.recursion.com in the case of Recursion, http://investors.exscientia.ai in the case of Exscientia, or www.sec.gov. All forward-looking statements are qualified by these cautionary statements and apply only as of the date they are made. Neither Recursion nor Exscientia undertakes any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional Information and Where to Find It
This communication relates to a proposed business combination of Recursion and Exscientia that will become the subject of a joint proxy statement to be filed by Recursion with the SEC. The joint proxy statement will provide full details of the proposed combination and the attendant benefits and risks, including the terms and conditions of the scheme of arrangement and the other information required to be provided to Exscientia’s shareholders under the applicable provisions of the U.K. Companies Act 2006. This communication is not a substitute for the joint proxy statement or any other document that Recursion or Exscientia may file with the SEC or send to their respective stockholders in connection with the proposed combination. Investors and security holders are urged to read the definitive joint proxy statement and all other relevant documents filed with the SEC or sent to Recursion’s stockholders or Exscientia’s shareholders as they become available because they will contain important information about the proposed combination. All documents, when filed, will be available free of charge at the SEC’s website (www.sec.gov). You may also obtain these documents by contacting Recursion’s Investor Relations department at investor@recursion.com; or by contacting Exscientia’s Investor Relations department at investors@exscientia.ai. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.
Participants in the Solicitation
Recursion, Exscientia and their respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed business combination. Information about Recursion’s directors and executive officers is available in Recursion’s proxy statement dated April 23, 2024 for its 2024 Annual Meeting of Stockholders. Information about Exscientia’s directors and executive officers is available in Exscientia’s proxy statement dated March 21, 2024 for its 2024 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement and all other relevant materials to be filed with the SEC regarding the proposed combination when they become available. Investors should read the joint proxy statement carefully when it becomes available before making any voting or investment decisions.
Bombardier is proud to partner with Alinghi Red Bull Racing as an Official Supplier in the year when the Swiss sailing team returns to claim the top spot in the America’s Cup.
Alinghi Red Bull Racing and Bombardier are likeminded partners, both at the pinnacle of engineering and innovation for uncompromising performance, be it over the waves or in the skies.
The Louis Vuitton 37th America’s Cup will take place between August and October 2024 in Barcelona, with Alinghi Red Bull Racing as one of five Challengers in competition.
MONTRÉAL, Aug. 08, 2024 (GLOBE NEWSWIRE) — Bombardier announced today it has joined forces with Alinghi Red Bull Racing as an official supplier. This new partnership brings together two teams devoted to pushing the boundaries, reaching the pinnacle of engineering and innovation in their pursuit to go faster, farther and better, be it over the waves or in the skies. The Alinghi Red Bull Racing team is returning this year in full force to compete in the most prestigious race in sailing, the America’s Cup, with its impressive BoatOne, just as Bombardier prepares to launch the Bombardier Global 8000, which will be the fastest business jet in the skies.
“We are excited to join forces with Alinghi Red Bull Racing, one of the most iconic teams in competitive sailing. Our partnership was born out of mutual respect and a likeminded approach in reaching the top of our respective fields,” said Stephen McCullough, Senior Vice President, Engineering and Product Development, Bombardier. “Our teams have much in common. All of us are dedicated to uncompromising performance. We master precision engineering and expert design, coupled with an intense drive for perpetual innovation. All of us at Bombardier are excited to add some wind to the sails of Alinghi Red Bull Racing as they reach for the very top in competitive sailing.”
The Swiss team is returning this year with a group composed of new sailors paired with America’s Cup winners from 2003 and 2007, bridging fierce devotion to invaluable experience. The team is further strengthened thanks to its new joint venture with Red Bull, which brings to the table the expertise of the Red Bull Advanced Technologies unit that has supported Red Bull Racing in achieving a total of seven Formula One Drivers’ Championships. All of this is setting the stage for Alinghi Red Bull Racing to be one of the most formidable challengers in the 37th America’s Cup, already making solid first impressions in the Preliminary Regattas in Vilanova i La Geltrú, Spain, and Jeddah, Saudi Arabia.
“We at Alinghi Red Bull Racing are delighted and feel privileged to have Bombardier accompanying us in our quest for the 37th America’s Cup. Today many of our designers have an aeronautical engineering background so we share very much the same passion and vision with Bombardier. And we are ready to take off together!” said Silvio Arrivabene, co-general manager at Alinghi Red Bull Racing.
“Racing sailboats like the Swiss team’s amazing BoatOne that fly above the waves on foils have more similarities with an aircraft than with how we typically imagine boats to look and move,” said McCullough, Bombardier’s chief of engineering who has been one of the driving visionary forces behind the development of Bombardier’s Global 7500 and Global 8000 jets. Just like the engineers at Alinghi Red Bull Racing push the limits in boat engineering to reach the highest speeds no matter the conditions, Bombardier has been breaking records on its own turf. The Bombardier Global 7500 jet holds over 40 industry speed records and counting, including the title of the longest-range flight in business aviation of 8,225 nautical miles. Bombardier is currently preparing the entry into service of its Global 8000 jet that is taking uncompromising performance even further. The jet has already made aviation history when it broke the speed of sound in testing, the first civilian aircraft to do so since the Concorde. This, along with the longest range and the smoothest ride in the industry, contributed to its latest accolade as the best private jet according to the editors of the 2024 Robb Report Monaco & Côte d’Azur best-of-the-best edition for the second year.
“The team at Alinghi Red Bull Racing embodies passion, innovation, speed, performance, and a boldness in pushing boundaries – all of which are values that have been driving us as well in developing the best jets in business aviation,” said Jean-Christophe Gallagher, Executive Vice President, Aircraft Sales & Bombardier Defense. “It is a true privilege to witness the performance the ARBR team is already delivering in this fascinating comeback, and we are excited that this partnership will allow us to share our window seat view of the world of competitive sailing with everyone who loves to see as much as we do innovative engineering and design in action, including our employees, customers, and other aviation fans.”
At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.
For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.
Bombardier customers operate a fleet of approximately 5,000 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico.
About Alinghi Red Bull Racing
After over a decade away from the Cup, Alinghi, one of the most dynamic names in the history of the America’s Cup, is returning to battle for sailing’s highest honour. The consecutive-winning syndicate joins forces with Red Bull, the driving force in global sport, to create a new team: Alinghi Red Bull Racing.
The team sails under the flag of the Société Nautique de Genève, is accompanied by its main partner Swiss watch brand TUDOR and co-partners Prysmian Group and UBS. The official Swiss challenger will compete in the Selection Series for the 37th America’s Cup, in 2024 in Barcelona. The countdown has begun!
For Information
For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book and Claim system visit bombardier.com.
Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.
Bombardier is proud to partner with Alinghi Red Bull Racing as an Official Supplier in the year when the Swiss sailing team returns to claim the top spot in the America’s Cup.
Alinghi Red Bull Racing and Bombardier are likeminded partners, both at the pinnacle of engineering and innovation for uncompromising performance, be it over the waves or in the skies.
The Louis Vuitton 37th America’s Cup will take place between August and October 2024 in Barcelona, with Alinghi Red Bull Racing as one of five Challengers in competition.
MONTRÉAL, Aug. 08, 2024 (GLOBE NEWSWIRE) — Bombardier announced today it has joined forces with Alinghi Red Bull Racing as an official supplier. This new partnership brings together two teams devoted to pushing the boundaries, reaching the pinnacle of engineering and innovation in their pursuit to go faster, farther and better, be it over the waves or in the skies. The Alinghi Red Bull Racing team is returning this year in full force to compete in the most prestigious race in sailing, the America’s Cup, with its impressive BoatOne, just as Bombardier prepares to launch the Bombardier Global 8000, which will be the fastest business jet in the skies.
“We are excited to join forces with Alinghi Red Bull Racing, one of the most iconic teams in competitive sailing. Our partnership was born out of mutual respect and a likeminded approach in reaching the top of our respective fields,” said Stephen McCullough, Senior Vice President, Engineering and Product Development, Bombardier. “Our teams have much in common. All of us are dedicated to uncompromising performance. We master precision engineering and expert design, coupled with an intense drive for perpetual innovation. All of us at Bombardier are excited to add some wind to the sails of Alinghi Red Bull Racing as they reach for the very top in competitive sailing.”
The Swiss team is returning this year with a group composed of new sailors paired with America’s Cup winners from 2003 and 2007, bridging fierce devotion to invaluable experience. The team is further strengthened thanks to its new joint venture with Red Bull, which brings to the table the expertise of the Red Bull Advanced Technologies unit that has supported Red Bull Racing in achieving a total of seven Formula One Drivers’ Championships. All of this is setting the stage for Alinghi Red Bull Racing to be one of the most formidable challengers in the 37th America’s Cup, already making solid first impressions in the Preliminary Regattas in Vilanova i La Geltrú, Spain, and Jeddah, Saudi Arabia.
“We at Alinghi Red Bull Racing are delighted and feel privileged to have Bombardier accompanying us in our quest for the 37th America’s Cup. Today many of our designers have an aeronautical engineering background so we share very much the same passion and vision with Bombardier. And we are ready to take off together!” said Silvio Arrivabene, co-general manager at Alinghi Red Bull Racing.
“Racing sailboats like the Swiss team’s amazing BoatOne that fly above the waves on foils have more similarities with an aircraft than with how we typically imagine boats to look and move,” said McCullough, Bombardier’s chief of engineering who has been one of the driving visionary forces behind the development of Bombardier’s Global 7500 and Global 8000 jets. Just like the engineers at Alinghi Red Bull Racing push the limits in boat engineering to reach the highest speeds no matter the conditions, Bombardier has been breaking records on its own turf. The Bombardier Global 7500 jet holds over 40 industry speed records and counting, including the title of the longest-range flight in business aviation of 8,225 nautical miles. Bombardier is currently preparing the entry into service of its Global 8000 jet that is taking uncompromising performance even further. The jet has already made aviation history when it broke the speed of sound in testing, the first civilian aircraft to do so since the Concorde. This, along with the longest range and the smoothest ride in the industry, contributed to its latest accolade as the best private jet according to the editors of the 2024 Robb Report Monaco & Côte d’Azur best-of-the-best edition for the second year.
“The team at Alinghi Red Bull Racing embodies passion, innovation, speed, performance, and a boldness in pushing boundaries – all of which are values that have been driving us as well in developing the best jets in business aviation,” said Jean-Christophe Gallagher, Executive Vice President, Aircraft Sales & Bombardier Defense. “It is a true privilege to witness the performance the ARBR team is already delivering in this fascinating comeback, and we are excited that this partnership will allow us to share our window seat view of the world of competitive sailing with everyone who loves to see as much as we do innovative engineering and design in action, including our employees, customers, and other aviation fans.”
At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.
For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.
Bombardier customers operate a fleet of approximately 5,000 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico.
About Alinghi Red Bull Racing
After over a decade away from the Cup, Alinghi, one of the most dynamic names in the history of the America’s Cup, is returning to battle for sailing’s highest honour. The consecutive-winning syndicate joins forces with Red Bull, the driving force in global sport, to create a new team: Alinghi Red Bull Racing.
The team sails under the flag of the Société Nautique de Genève, is accompanied by its main partner Swiss watch brand TUDOR and co-partners Prysmian Group and UBS. The official Swiss challenger will compete in the Selection Series for the 37th America’s Cup, in 2024 in Barcelona. The countdown has begun!
For Information
For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book and Claim system visit bombardier.com.
Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.
Bombardier is proud to partner with Alinghi Red Bull Racing as an Official Supplier in the year when the Swiss sailing team returns to claim the top spot in the America’s Cup.
Alinghi Red Bull Racing and Bombardier are likeminded partners, both at the pinnacle of engineering and innovation for uncompromising performance, be it over the waves or in the skies.
The Louis Vuitton 37th America’s Cup will take place between August and October 2024 in Barcelona, with Alinghi Red Bull Racing as one of five Challengers in competition.
MONTRÉAL, Aug. 08, 2024 (GLOBE NEWSWIRE) — Bombardier announced today it has joined forces with Alinghi Red Bull Racing as an official supplier. This new partnership brings together two teams devoted to pushing the boundaries, reaching the pinnacle of engineering and innovation in their pursuit to go faster, farther and better, be it over the waves or in the skies. The Alinghi Red Bull Racing team is returning this year in full force to compete in the most prestigious race in sailing, the America’s Cup, with its impressive BoatOne, just as Bombardier prepares to launch the Bombardier Global 8000, which will be the fastest business jet in the skies.
“We are excited to join forces with Alinghi Red Bull Racing, one of the most iconic teams in competitive sailing. Our partnership was born out of mutual respect and a likeminded approach in reaching the top of our respective fields,” said Stephen McCullough, Senior Vice President, Engineering and Product Development, Bombardier. “Our teams have much in common. All of us are dedicated to uncompromising performance. We master precision engineering and expert design, coupled with an intense drive for perpetual innovation. All of us at Bombardier are excited to add some wind to the sails of Alinghi Red Bull Racing as they reach for the very top in competitive sailing.”
The Swiss team is returning this year with a group composed of new sailors paired with America’s Cup winners from 2003 and 2007, bridging fierce devotion to invaluable experience. The team is further strengthened thanks to its new joint venture with Red Bull, which brings to the table the expertise of the Red Bull Advanced Technologies unit that has supported Red Bull Racing in achieving a total of seven Formula One Drivers’ Championships. All of this is setting the stage for Alinghi Red Bull Racing to be one of the most formidable challengers in the 37th America’s Cup, already making solid first impressions in the Preliminary Regattas in Vilanova i La Geltrú, Spain, and Jeddah, Saudi Arabia.
“We at Alinghi Red Bull Racing are delighted and feel privileged to have Bombardier accompanying us in our quest for the 37th America’s Cup. Today many of our designers have an aeronautical engineering background so we share very much the same passion and vision with Bombardier. And we are ready to take off together!” said Silvio Arrivabene, co-general manager at Alinghi Red Bull Racing.
“Racing sailboats like the Swiss team’s amazing BoatOne that fly above the waves on foils have more similarities with an aircraft than with how we typically imagine boats to look and move,” said McCullough, Bombardier’s chief of engineering who has been one of the driving visionary forces behind the development of Bombardier’s Global 7500 and Global 8000 jets. Just like the engineers at Alinghi Red Bull Racing push the limits in boat engineering to reach the highest speeds no matter the conditions, Bombardier has been breaking records on its own turf. The Bombardier Global 7500 jet holds over 40 industry speed records and counting, including the title of the longest-range flight in business aviation of 8,225 nautical miles. Bombardier is currently preparing the entry into service of its Global 8000 jet that is taking uncompromising performance even further. The jet has already made aviation history when it broke the speed of sound in testing, the first civilian aircraft to do so since the Concorde. This, along with the longest range and the smoothest ride in the industry, contributed to its latest accolade as the best private jet according to the editors of the 2024 Robb Report Monaco & Côte d’Azur best-of-the-best edition for the second year.
“The team at Alinghi Red Bull Racing embodies passion, innovation, speed, performance, and a boldness in pushing boundaries – all of which are values that have been driving us as well in developing the best jets in business aviation,” said Jean-Christophe Gallagher, Executive Vice President, Aircraft Sales & Bombardier Defense. “It is a true privilege to witness the performance the ARBR team is already delivering in this fascinating comeback, and we are excited that this partnership will allow us to share our window seat view of the world of competitive sailing with everyone who loves to see as much as we do innovative engineering and design in action, including our employees, customers, and other aviation fans.”
At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.
For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.
Bombardier customers operate a fleet of approximately 5,000 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico.
About Alinghi Red Bull Racing
After over a decade away from the Cup, Alinghi, one of the most dynamic names in the history of the America’s Cup, is returning to battle for sailing’s highest honour. The consecutive-winning syndicate joins forces with Red Bull, the driving force in global sport, to create a new team: Alinghi Red Bull Racing.
The team sails under the flag of the Société Nautique de Genève, is accompanied by its main partner Swiss watch brand TUDOR and co-partners Prysmian Group and UBS. The official Swiss challenger will compete in the Selection Series for the 37th America’s Cup, in 2024 in Barcelona. The countdown has begun!
For Information
For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book and Claim system visit bombardier.com.
Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.
SYDNEY, Australia, Aug. 08, 2024 (GLOBE NEWSWIRE) — Last summer, leading global Forex and CFD broker Axi launched Axi Select, a pioneering capital allocation program offering ambitious traders the opportunity to progress into professional trading. Over the past year, thousands of traders have joined Axi Select, and now, they are sharing their success stories through a new series Axi Select Talks.
“First of all, you don’t have to pay a subscription fee, just a minimum deposit. And they really give you the chance to earn money… They have a few clear rules that make sense for both parties, and not just for the broker,” says Gerald Wintersberger, software engineer, when talking about Axi Select. As a seasoned trader, he is the first to reach Pro stage and is making steady advancement towards securing $1,000,000 in funding. Stories of other traders like Gerald would be featured in the Axi Select Talks podcast series.
Following the recent chaos that has shaken the prop trading industry resulting in numerous firms getting shut down, Axi Select seems to be the most promising choice. The trader-centric model is designed to offer traders a fair pathway to access capital funding up to $1,000,000 USD and the opportunity to earn up to 90% of their profits. Furthermore, traders have the advantage to join the program with zero registration fees, as well as benefit, among others, from unrestrictive trading conditions, and an exclusive trading room.
The Axi Select program is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. In our dealings with you, we will act as a principal counterparty to all of your positions. This content is not available to AU, NZ, EU and UK residents. For more information, refer to our Terms of Service.
About Axi
Axi is a global online FX and CFD trading company, with thousands of customers in 100+ countries worldwide. Axi offers CFDs for several asset classes including Forex, Shares, Gold, Oil, Coffee, and more.
At Axi, we are proud of our reputation as an honest, and fair broker, providing our customers with outstanding service and trading conditions since 2007. We also work with leading regulatory governing authorities globally to ensure we exceed the highest standards in the industry.
GlobeNewswire Distribution ID 9201657